Welcome to our dedicated page for Amphastar Pharmaceuticals news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharmaceuticals stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Established in 1996, Amphastar is known for developing, manufacturing, and marketing injectable and inhalation products using state-of-the-art, cGMP-compliant facilities. The company operates five manufacturing facilities across the United States, China, and Europe, along with a cutting-edge new drug research center.
Amphastar's core business revolves around producing approximately 15 injectable products, with a strong focus on both generic and branded drugs that target large markets with high technical barriers to entry. The company's comprehensive portfolio includes injectable, inhalation, and intranasal products, catering to hospitals and urgent care clinical settings. These products are distributed through group purchasing organizations and drug wholesalers, with the majority of revenue being generated in the United States.
The company leverages its longstanding relationships with major group purchasing organizations and drug wholesalers in the U.S. to establish significant market share quickly. Amphastar's finished pharmaceutical products and Active Pharmaceutical Ingredient (API) products are divided into two main segments: Finished Pharmaceutical Products and API Products.
Recent achievements for Amphastar include the acquisition of commercially successful products like BAQSIMI® and the strategic expansion of their diabetes portfolio. The company reported impressive financial results for the third quarter of 2023, with net revenues of $180.6 million and a GAAP net income of $49.2 million. The strong performance was driven by their diabetes portfolio and the newly acquired BAQSIMI®.
Amphastar's product development pipeline is robust, with multiple ANDAs and biosimilar products targeting significant market opportunities. The company also announced the FDA approval of Albuterol Sulfate Inhalation Aerosol, marking a milestone in their ability to develop complex generic inhalation products. This approval reflects Amphastar’s technological and manufacturing expertise, positioning the company for future growth.
Amphastar's commitment to quality and innovation is further demonstrated by their strategic acquisition and integration activities, focused on maximizing commercial potential and delivering high-quality pharmaceutical solutions. The company continues to enhance its pipeline with both generic and proprietary products, targeting products with large market sizes and high growth potential.
For more information, visit www.amphastar.com.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Bill Peters, CFO, and Dan Dischner, SVP of Corporate Communication, will engage in an analyst-moderated fireside chat on December 4th, 2024 at 11:30 am EST. The presentation will be accessible through Amphastar's website at ir.amphastar.com, with the webcast remaining available for 30 days after the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the Jefferies London Healthcare Conference. CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will engage in an analyst-moderated fireside chat on Wednesday, November 20, 2024, at 3:30 pm GMT. The presentation will be accessible through Amphastar's website at http://ir.amphastar.com, with the webcast remaining available for 30 days after the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q3 2024 financial results with net revenues of $191.2 million, up 6% year-over-year. The company achieved GAAP net income of $40.4 million ($0.78 per share) and adjusted non-GAAP net income of $49.6 million ($0.96 per share). BAQSIMI® contributed significantly with $40.4 million in direct sales, while Primatene MIST® sales increased 5% to $26.1 million. The Board authorized a $50 million increase to the share buyback program. Operating cash flow for the first nine months was $184.4 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its third quarter 2024 earnings release and conference call for November 6, 2024. The financial results will be released after market close, followed by a conference call at 2:00 p.m. Pacific Time. Investors can access the call via toll-free number 877-407-0989 or international number 201-389-0921. The call will also be available through the company's website, with a replay accessible within 24 hours after the live conference.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the 2024 Wells Fargo Healthcare Conference. Key details include:
- CFO Bill Peters and EVP Tony Marrs will engage in a fireside chat
- The event is scheduled for Thursday, September 5, 2024, at 10:15 am EST
- Access to the presentation will be available on Amphastar's website at http://ir.amphastar.com
- The webcast will remain accessible for 30 days following the presentation
This participation underscores Amphastar's commitment to engaging with investors and sharing insights about the company's operations and future prospects in the pharmaceutical industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported strong financial results for Q2 2024. Key highlights include:
- Net revenues of $182.4 million, up 25% year-over-year
- GAAP net income of $37.9 million, or $0.73 per share
- Adjusted non-GAAP net income of $48.7 million, or $0.94 per share
The company's performance was driven by:
- BAQSIMI® sales of $30.9 million
- Epinephrine sales increase of 67% to $27.9 million
- Primatene MIST® sales growth of 38% to $22.9 million
Gross profit margin improved to 52.2% from 49.9% in Q2 2023. The company's pipeline includes 3 ANDAs, 3 biosimilars, and 4 generic products in development, targeting markets worth over $13 billion.
Amphastar Pharmaceuticals (NASDAQ:AMPH), a bio-pharmaceutical company specializing in technically challenging generic and proprietary injectable, inhalation, and intranasal products, has announced its second quarter 2024 earnings release and conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Wednesday, August 7, 2024. A conference call to discuss these results is scheduled for 2:00 p.m. Pacific Time on the same day.
Investors can access the call by dialing 877-407-0989 (toll-free) or 201-389-0921 (international). The call will also be available via webcast on the company's website, with a replay accessible within 24 hours after the live call ends. Amphastar's products are primarily used in hospital or urgent care settings and are distributed through group purchasing organizations and drug wholesalers.
BetterInvesting Magazine has announced Amphastar Pharmaceuticals (NASDAQ: AMPH) as its 'Stock to Study' and Medtronic (NYSE: MDT) as its 'Undervalued Stock' for the September 2024 issue. The National Association of Investors Corp. (NAIC) encourages investors to focus on fundamentals and informed decision-making. The magazine's choices are informational and educational, not endorsements. A trial version of BetterInvesting's tools is available for non-members to analyze these stocks. The committee includes several CFA members who review the stocks, emphasizing investor education. Full details will be available in the magazine's September issue.
Amphastar Pharmaceuticals (NASDAQ: AMPH) has announced a $50 million increase to its share buyback program, effective from June 3, 2024. This initiative aims to counterbalance a dilution caused by the company's equity compensation programs. The repurchases will be made through various means, including open market and private block transactions. The company currently has three ANDAs filed with the FDA, targeting a market size of over $1.4 billion, and is developing three biosimilar products with a market size of over $7 billion and four generic products targeting over $3 billion. Amphastar's subsidiary in China, ANP, has multiple DMFs filed with the FDA and is developing additional DMFs. Amphastar primarily focuses on developing and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products, along with insulin API products.
Amphastar Pharmaceuticals announced that its CFO, Bill Peters, and EVP of Corporate Administration, Jacob Liawatidewi, will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for June 6, 2024, at 12:30 pm EST. The discussion will be moderated by an analyst and focus on the company's strategic initiatives and financial outlook. Investors can access the webcast through Amphastar's website, which will be available for 30 days following the presentation.
FAQ
What is the current stock price of Amphastar Pharmaceuticals (AMPH)?
What is the market cap of Amphastar Pharmaceuticals (AMPH)?
What does Amphastar Pharmaceuticals, Inc. specialize in?
Where are Amphastar’s manufacturing facilities located?
What are Amphastar’s main product segments?
What recent product approval has Amphastar received from the FDA?
How does Amphastar distribute its products?
What significant acquisition has Amphastar completed recently?
What are the financial highlights for Amphastar’s third quarter of 2023?
What is the focus of Amphastar’s product development pipeline?
Where can I find more information about Amphastar Pharmaceuticals?
What are some key products in Amphastar’s portfolio?
